Public Policy Victories

In October, the bipartisan NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act were signed into law by the president, which will continue the critical work of the National Plan to Address Alzheimer’s Disease.

Read More

Secured a $100 million increase for Alzheimer’s and dementia research funding at the National Institutes of Health (NIH) and $34 million to continue to implement the BOLD Infrastructure for Alzheimer’s Act (P.L. 115-406).

Read More

In July, the Centers for Medicare & Medicaid Services (CMS) announced a new initiative to improve the way dementia care is delivered. This test initiative, the Guiding an Improved Dementia Experience (GUIDE) Model, will be run through the Center for Medicare & Medicaid Innovation (CMMI). The CMS decision came following the rapidly growing support our advocates generated for the Comprehensive Care for Alzheimer's Act.

Read More

Secured $289 million increase in federal research funding and $25 million to implement the BOLD Infrastructure for Alzheimer's Act (P.L. 115-406).

Read More

Ensured Americans living with dementia under the age of 60 can now utilize nutritional services, supportive services, and respite care through the National Family Caregiver Support program.

Read More

Together with our advocates, we advanced the Promoting Alzheimer’s Awareness to Prevent Elder Abuse Act to protect people with dementia from elder abuse.

Read More

The Association and AIM championed the Improving HOPE for Alzheimer’s Act to educate providers and increase utilization of critical care planning services available through Medicare.

Read More

Grew support for a $300 million Alzheimer’s and dementia research funding increase at the NIH. Today, federal funding is $3.2 billion annually, representing a more than seven-fold increase in research funding since NAPA passed.

Read More

Worked with bipartisan Congressional champions to secure an additional $350 million in federal research funding. Today funding for Alzheimer's and dementia research at the National Institutes of Health (NIH) is $2.8 billion annually, and representing a more than six-fold increase in research funding since the passage of the National Alzheimer's Project Act.

Read More

In December, Congress passed and the president signed into law the BOLD Infrastructure for Alzheimer's Act, legislation developed in close partnership between the Alzheimer's Association, AIM and congressional champions.

Read More

In September, Congress passed and the President signed into law a $425 million increase for Alzheimer’s research funding at the NIH in the FY2019 budget, bringing total annual funding to $2.3 billion.

Read More

The president signed the RAISE Family Caregivers Act to address the needs of our nation's family caregivers through the development and implementation of a coordinated national strategy.

Read More

In March, Congress passed and the president signed a $414 million increase for Alzheimer’s research funding at the National Institutes of Health (NIH) for FY2018. This marked the third consecutive year of triple digit funding increases. In May, Congress passed and the President signed a historic $400 million increase for Alzheimer’s research funding at the NIH in the FY2017 budget.

Read More

In May, Congress passed and the President signed a historic $400 million increase for Alzheimer’s research funding at the NIH in the FY2017 budget.

Read More

In December, Congress passed and the president signed into law the 21st Century Cures Act, legislation with a goal of accelerating the discovery, development and delivery of new cures for all diseases including Alzheimer’s and other dementia. The legislation included $1.6 billion for BRAIN Initiative and an additional $1.5 billion for the Precision Medicine Initiative. The legislation also includes the EUREKA Act which will help to advance research breakthroughs for Alzheimer’s disease, and encourage public-private partnerships.

In November, The Centers for Medicare & Medicaid Services (CMS) finalized its decision to pay for cognitive and functional assessment and for care planning services with a professional for those with Alzheimer’s, other dementia and cognitive impairment. The decision by CMS came following the rapidly growing support our advocates and staff have generated for the Health Outcomes, Planning and Education (HOPE) for Alzheimer's Act in Congress.

Read More

In December, Congress passed and the president signed into law the FY2016 Omnibus Appropriations Bill, which included a $350 million increase for Alzheimer’s disease research at the NIH. This is the largest annual increase ever in federal Alzheimer’s research funding — a nearly 60 percent increase.

Read More

In December, Montana became the forty-sixth state plus the District of Columbia and Puerto Rico to publish a state Alzheimer’s plans to address and prepare for the Alzheimer’s crisis.

In July, the first Professional Judgment Budget for Alzheimer's research was released by the NIH, proposing to the U.S. Congress the continuation of a rapid ramp-up in Alzheimer's research funding. This budget is a direct result of the Alzheimer's Accountability Act, an Alzheimer's Association priority.

Read More

In December, Congress passed and the president signed into law the FY2015 Omnibus Appropriations Bill, incorporating the entirety of the Alzheimer's Accountability Act into the legislation. This legislation calls for the NIH to submit a Professional Judgment Budget for Alzheimer's disease research each year until 2025 to achieve annual research milestones established under the National Alzheimer's Plan.

Read More

Legislation is passed and signed which provided an additional $122 million in the FY14 budget for Alzheimer's research, education, outreach and caregiver support. This included $100 million for research, $20 million more than was in the president's FY14 budget request.

Read More

The 40th state enacted the Uniform Adult Guardianship and Protective Proceedings Jurisdiction Act (UAGPPJA) which establishes a framework for courts in different states to communicate about adult guardianship cases.

The Director of the NIH, Dr. Francis Collins provided $40 million from the Director's budget for additional Alzheimer's research, which he announced at the annual Advocacy Forum.

The Federal District Court of Vermont approved the proposed settlement agreement in the Jimmo v. Sebelius class action lawsuit which sought to end the application of the “improvement standard” as the basis for Medicare coverage decisions for skilled therapies. The Alzheimer's Association was a plaintiff in the class action lawsuit and supported the settlement agreement.

The first-ever National Alzheimer's Plan was released by the administration in May 2012. In connection with the plan's release, Alzheimer's received an additional $50 million in federal research funding during the fiscal year.

Read More

One of the Association's top legislative priorities, the National Alzheimer's Project Act (S.3036), was signed into law.

Read More

The two-year waiting period for Social Security Disability (SSDI) for those diagnosed with younger or early onset Alzheimer's disease is eliminated. This change provides expedited access to SSDI and Supplemental Security Income (SSI).

For the first time, the decennial Healthy People Report included objectives for Alzheimer's and other dementias underscoring the growing public health threat they pose to the nation.

The Alzheimer's Association helps advance a new Medicare benefit that includes the detection of cognitive impairment as part of the annual wellness visit beginning January 2011.

The Alzheimer's Association ensured that the Patient Protection and Affordable Care Act contained provisions to help people with Alzheimer's disease, their families and their caregivers, such as a federal long-term care insurance program.

Read More

Secured an additional $10 billion for the NIH in the American Recovery and Reinvestment Act ("stimulus bill"). Of the $5 billion awarded so far, the NIH has invested $77 million in Alzheimer's grants. The Alzheimer's Disease Neuroimaging Initiative was among the studies to receive funding.

Read More

Established the leading standard of quality for nursing homes and assisted living by offering practice recommendations and training for professional providers, as part of our Quality Care Campaign.

Gained inclusion of Alzheimer's medicines in Medicare's Drug Formulary (covered drugs).

Won passage of Medicare's Part D Drug Benefit, which went into effect in 2006.

Secured rehabilitation benefits for Medicare beneficiaries with Alzheimer's disease so individuals were no longer denied this coverage.

Won passage of the Family Caregiver Support Program, included within the Older Americans Act. The program supports a number of community-based programs, including respite care, adult day care, counseling services and caregiver training.